Boletín de AInvest
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Novo Nordisk's new Wegovy pill has achieved 3,071 US prescriptions in its first four days, indicating strong initial demand. The company is a global leader in diabetes care with a significant market share in branded diabetes treatments. Financial metrics reveal robust profitability and growth, with an operating margin of 42.03% and a three-year revenue growth rate of 28.6%.

Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Comentarios
Aún no hay comentarios